An antisense method for efficient exon skipping and its application to Duchenne muscular dystrophy
Proceedings of the National Academy of Sciences · 18.08.2026 · 123 (33)
DOI: 10.1073/pnas.2606494123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 10.08.2026. Verfasst von Pengchao Feng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing Antisense Biopharm, Nanjing, Jiangsu 210023, China. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Exons, Oligonucleotides, Antisense, Dystrophin. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ASOcura Pharmaceuticals, Nanjing Antisense Biopharm, St. Giles Foundation (St Giles Foundation).
Abstract (Originalsprache)
Antisense-mediated exon skipping has been used to treat Duchenne muscular dystrophy (DMD) by restoring the DMD reading frame to express partially functional dystrophin. However, difficulty in designing effective antisense oligonucleotides (ASOs) has hindered the development of clinically effective therapies. Here we describe a robust bipartite ASO design, termed 5′ splice site decoy (5D)-ASO, in which a short tail sequence is employed to enhance the splicing repression exerted by an antisense moiety. The tail carried by the antisense moiety to an exon of interest in a target pre-mRNA interferes with the recognition of the exon’s 5′ splice site by U1 snRNA and markedly enhances exon skipping, compared to tail-less ASOs. 5D-ASO has broad applicability, based on multiple genes tested. Particularly, an 8-nt tail, when appended to sequences targeting DMD exon 51, elicited a pronounced increase in exon skipping in mouse models, restored dystrophin expression in muscle tissues and improved the phenotype, without obvious signs of toxicity. The lead ASO further demonstrated a marked exon-skipping effect and an overall safe profile in monkeys. Our data establish a valuable platform technology for RNA-targeted therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanjing Antisense Biopharm, Nanjing, Jiangsu 210023, China.
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu 210023, China.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724.
- Guangzhou Asocura Pharmaceuticals, Guangzhou, Guangdong 510535, China.
ORCID-Profile: Adrian R Krainer
Förderung
- ASOcura Pharmaceuticals
- Nanjing Antisense Biopharm
- St. Giles Foundation (St Giles Foundation)
- HHS | NIH | National Institute of General Medical Sciences (NIGMS)
- NIGMS NIH HHS
Zitieren
APA
Feng, P., Gao, P., Meng, S., Yuan, Y., Krainer, A. R., & Hua, Y. (2026). An antisense method for efficient exon skipping and its application to Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences, 123(33). https://doi.org/10.1073/pnas.2606494123
Vancouver
Feng P, Gao P, Meng S, Yuan Y, Krainer AR, Hua Y. An antisense method for efficient exon skipping and its application to Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences. 2026;123(33). doi:10.1073/pnas.2606494123
BibTeX
@article{Feng2026,
author = {Feng, Pengchao and Gao, Peng and Meng, Shaodong and Yuan, Yunxia and Krainer, Adrian R and Hua, Yimin},
title = {An antisense method for efficient exon skipping and its application to Duchenne muscular dystrophy},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {33},
doi = {10.1073/pnas.2606494123}
}
EUVIMED